Published in Eur J Surg Oncol on December 01, 2004
Segmental resection of the duodenum for gastrointestinal stromal tumor (GIST). World J Surg Oncol (2008) 1.49
Segmental duodenectomy for gastrointestinal stromal tumor of the duodenum. World J Gastroenterol (2010) 1.14
Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg (2008) 1.13
Limited resection for duodenal gastrointestinal stromal tumors: Surgical management and clinical outcome. World J Gastrointest Surg (2013) 1.07
Endoscopic treatment for gastrointestinal stromal tumor: Advantages and hurdles. World J Gastrointest Endosc (2015) 1.01
Gastrointestinal stromal tumors: correlation between symptoms at presentation, tumor location and prognostic factors in 47 consecutive patients. World J Surg Oncol (2011) 0.99
Surgical margin status and prognosis of gastrointestinal stromal tumor. World J Surg (2008) 0.97
Gastrointestinal stromal tumor of stomach with inguinal lymph nodes metastasis: a case report. World J Gastroenterol (2010) 0.91
Gastrointestinal stromal tumor of the stomach with lymph node metastasis. World J Surg Oncol (2008) 0.90
Gastrointestinal stromal tumors (GISTs): an updated experience. Dig Dis Sci (2010) 0.89
Laparoscopic resection of sporadic synchronous gastric and jejunal gastrointestinal stromal tumors: report of a case. Surg Today (2009) 0.88
Laparoscopic versus open resection of gastric gastrointestinal stromal tumors. Chin J Cancer Res (2013) 0.88
Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment. Ther Clin Risk Manag (2010) 0.85
Simple segmental resection of the second portion of the duodenum for the treatment of gastrointestinal stromal tumors. Langenbecks Arch Surg (2007) 0.85
Acute abdomen caused by nontraumatic hemoperitoneum is the first manifestation of gastric low grade stromal tumor. World J Emerg Med (2012) 0.83
Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. World J Gastroenterol (2009) 0.82
Gastrointestinal stromal tumors-diagnosis and management: a brief review. Ochsner J (2008) 0.81
Clinicopathological features of primary jejunoileal tumors. J Korean Soc Coloproctol (2010) 0.81
The outcome of gastrointestinal stromal tumors (GISTs) after a surgical resection in our institute. Surg Today (2007) 0.81
Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours. Langenbecks Arch Surg (2008) 0.80
Colorectal gastrointestinal stromal tumor. Tech Coloproctol (2010) 0.79
Giant esophageal gastrointestinal stromal tumor: report of a case. Surg Today (2014) 0.78
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model. BMC Cancer (2014) 0.76
MDCT features of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours. Br J Radiol (2014) 0.76
Prognostic factors affecting survival after surgical resection of gastrointestinal stromal tumours: a two-unit experience over 10 years. World J Surg Oncol (2006) 0.75
Primary Small Bowel GIST Presenting as a Life-Threatening Emergency: A Report of Two Cases. Case Rep Surg (2017) 0.75
Supraclavicular lymph node metastases from malignant gastrointestinal stromal tumor of the jejunum: A case report with review of the literature. World J Gastroenterol (2017) 0.75
Concomitant gastrointestinal stromal tumor of the stomach and gastric adenocarcinoma in a patient with billroth 2 resection. Case Rep Surg (2013) 0.75
The predictive value of preoperative (18)F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour. Eur Radiol (2016) 0.75
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol (2005) 5.82
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg (2011) 2.91
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer (2009) 2.52
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer (2001) 2.25
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol (2007) 2.15
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol (2008) 2.10
Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med (2000) 2.08
Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology (1999) 2.01
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer (1998) 1.96
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol (2000) 1.95
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol (2009) 1.92
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer (2001) 1.92
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol (1998) 1.80
Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg (1998) 1.79
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer (2001) 1.78
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg (1995) 1.64
Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol (2005) 1.59
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol (2010) 1.58
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol (2002) 1.55
Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg (1998) 1.54
The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol (2012) 1.53
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer (2004) 1.52
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol (2004) 1.51
Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene (2007) 1.50
Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol (2007) 1.45
[Percutaneous radiofrequency ablation of hepatic metastases. Preliminary experience]. Gastroenterol Clin Biol (1999) 1.45
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. Ann Oncol (2001) 1.44
Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol (1998) 1.43
[What are the real indications for hepatectomies in metastases of colorectal origin?]. Gastroenterol Clin Biol (1998) 1.39
[Is sentinel lymph node mapping relevant for colon cancer?: a feasibility study]. Ann Chir (2003) 1.39
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest (1997) 1.39
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol (2005) 1.39
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study. Radiother Oncol (1997) 1.38
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol (2003) 1.36
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol (1998) 1.34
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer (2001) 1.30
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol (2011) 1.29
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol (1996) 1.27
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer (2011) 1.27
Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer (2000) 1.26
Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol (1998) 1.26
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol (2009) 1.26
Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action. Cancer Treat Rev (2013) 1.24
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol (1998) 1.23
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer (1998) 1.23
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer (2009) 1.22
Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol (2010) 1.22
Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract (2012) 1.21
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer (1994) 1.21
Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol (1996) 1.21
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer (2007) 1.19
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res (2000) 1.17
Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Ann Oncol (2013) 1.16
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev (2013) 1.16
Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer (2003) 1.14
High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer (2010) 1.14
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol (2011) 1.14
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol (1999) 1.14
Liver abscess formation after local treatment of liver tumors. Hepatology (1996) 1.13
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer (2003) 1.12
Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol (2002) 1.12
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol (2012) 1.11
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol (2011) 1.10
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bull Cancer (1999) 1.10
Docetaxel and interstitial pulmonary injury. Ann Oncol (1997) 1.09
Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol (2013) 1.08
Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol (2006) 1.08
[Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis]. Ann Dermatol Venereol (1999) 1.06
Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology (1993) 1.06